Issue 12 – December 2016

First-line Glaucoma Therapy: Choices and Challenges
Tony Realini, MD, MPH

The Association Between Myopia and Glaucoma
Terri L. Young, MD, MBA

Learning Objectives:

• Compare SLT with medical therapy as first-line therapy for the management of OAG.

• Develop appropriate treatment goals for patients with newly diagnosed OAG based on disease status and risk profile.

• Describe the epidemiology of myopia and the pathophysiological mechanisms by which glaucoma develops in myopic eyes.

• Describe techniques for detecting early glaucomatous changes in myopic eyes and potential therapeutic interventions for preventing myopia and progression to glaucoma.

Issue 11 – November 2016

Medication-related Ocular Surface Disorders Among Glaucoma Patients
Christophe Baudouin, MD, PhD

Secondary Glaucoma: Beyond Exfoliative and
Pigmentary Glaucoma
Leon W. Herndon, MD

Learning Objectives:

• Identify factors that contribute to ocular surface disorders among patients undergoing medical treatment for glaucoma.

• Modify management to counter ocular surface disease in glaucoma patients. 

• Describe the main categories and clinical presentation of secondary glaucomas outside of the exfoliative and pigmentary types.

• Describe treatment management strategies, and anticipated complications that may be involved, for these secondary glaucomas.

Issue 10 – September 2016

Pseudoexfoliation and Pigmentary Glaucomas
Kimberly V. Miller, MD

Heads Up: Lesser-known Glaucoma Risk Factors and Therapeutic Targets
Robert Ritch, MD

Learning Objectives:

• Improve differential diagnosis of PXF and pigmentary glaucomas.

• Appropriately use different treatment modalities in the management of PXF or pigmentary glaucoma to control IOP and prevent disease progression.

• Identify patients with posture- or sleep-related factors that may be exacerbating their glaucoma.

• Recognize the role of sleep apnea and vascular dysregulation on glaucoma physiology and management.

Issue 9 – June 2016

Approaches to Anti-Glaucoma Medication Nonadherence
William C. Stewart, MD

Glaucoma Drug Delivery: New Advances 
James D. Brandt, MD

Learning Objectives:

• Identify barriers to medication adherence among their patients.

• Take steps to reduce nonadherence among glaucoma patients.

• Identify glaucoma patients who may benefit from sustained-release therapies by increasing awareness of nonadherence with eye drop treatment.

• Compare different drug-delivery systems developed for glaucoma based on considerations of efficacy, safety, and practicality.

Issue 8 – April 2016

Ocular Perfusion Pressure: An Important New Parameter?
Jost Jonas, MD

Managing Ocular Hypertension: a Practical Approach
Anthony Realini, MD, MPH

Learning Objectives:

• Assess the significance of ocular perfusion pressure as a risk factor for glaucoma.

• Outline the potential role of low CSFP in the development of glaucomatous damage.

• List the significant risk factor for the development of glaucoma in patients with ocular hypertension.

• Devise appropriate management plans based on patients’ risk profiles and suitability for treatment.

Issue 7 – March 2016

Normal Tension Glaucoma: Current Understanding and Management
Grace Richter, MD, MPH

Ocular Structural Factors Related to Risk of Open Angle Glaucoma
Christopher T. Girkin, MD

Learning Objectives:

• Review etiologic factors that may contribute to the development and progression of NTG.

• Differentially diagnose NTG from POAG and nonglaucomatous optic neuropathies based on clinical findings.

• Describe proven risk factors for POAG, including anatomical/structural risk factors.

• Characterize the relationship between IOP and CCT.

Issue 6 – December 2015

Evaluating Glaucoma Progression
Yao Liu, MD

The Future of Glaucoma Treatment
Keith Martin, MD

Learning Objectives:

• Combine structural and functional assessments to evaluate glaucoma progression.

• Optimize frequency of optic nerve and visual field evaluations to monitor the status of glaucoma.

• Cite anticipated changes in glaucoma management in the next 5 to 10 years.

• Discuss the potential for nerve regeneration as a treatment for glaucoma.

Issue 5 – November 2015

The Clinical Meaning of Intraocular Pressure Fluctuation
Sanjay G. Asrani, MD

Lifestyle and Other Non-pharmaceutical Approaches to Managing Glaucoma
Robert Ritch, MD

Learning Objectives:

• Differentiate normal and abnormal IOP fluctuation.

• Detect and manage IOP fluctuation in appropriate patients.

• Evaluate potentially IOP-lowering strategies related to posture and biophysics.

• Discuss and recommend plant and lifestyle-based modalities to glaucoma patients.

Issue 4 – October 2015

Preventing Primary Angle Closure Glaucoma
Prof Tin Aung, MMed(Ophth), FRCS(Ed), FRCOphth(UK), FAMS, PhD(Lond)

Cataract Surgery and Glaucoma
David S. Friedman, MD, MPH, PhD

Learning Objectives:

• Identify patients at risk for PACG.

• Describe the requirements and tools for PACG diagnosis.

• Describe the effect of cataract surgery on IOP and state proposed mechanisms for this effect.

• Take into consideration the IOP-lowering effect of cataract surgery in selecting the appropriate surgical treatment for coexisting cataract and glaucoma.

Issue 3 – September 2015

New Drugs in Glaucoma Treatment
Paul L. Kaufman, MD

Measuring IOP: The Technology and Its Limitations
James C. Tsai, MD, MBA

Learning Objectives:

• Distinguish current glaucoma medications based on their mechanisms of action.

• List three new drugs that are being developed to treat glaucoma.

• Devise a viable strategy for IOP measurement within their practice.

• Describe the limitations of technologies they are currently using for IOP measurement.

Issue 2 – August 2015

Medical Therapy for Intraocular Pressure Reduction
L. Jay Katz, MD

Aqueous Humor Dynamics, Intraocular Pressure, and Glaucoma
W. Daniel Stamer, PhD

Learning Objectives:

• Create a staged management plan for patients with glaucoma.

• List steps to take in the event that target IOP is not maintained.

• Describe structural and functional bases of aqueous humor formation and outflow.

• Use aqueous humor pathophysiology to interpret ocular hypertension and the mechanisms of action of current pharmacological therapies for glaucoma.  

Issue 1 – July 2015

Who Has Glaucoma? Definitions and Diagnosis
Stephen L. Mansberger, MD, MPH

Medical Treatment of Glaucoma
Jonathan S. Myers, MD

Learning Objectives:

• Define glaucoma and common subtypes.

• Discuss the role of IOP in glaucoma diagnosis.

• Characterize four classes of IOP-lowering medication.

• State the rationale for medical therapy in the treatment of primary and secondary glaucomas.